Shield welcomes US clearance of heart attack test but says Afecta is not all it has to offer
This article was originally published in Clinica
Shield Diagnostics' heart attack prediction test, Afecta, received US marketing clearance last week. This is a significant milestone, but as managing director David Evans told Maureen Kenny, Shield is keen not to be seen as a one-product company.
You may also be interested in...
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.